CTD²: Cancer Target Discovery and Development

The Cancer Target Discovery and Development (CTD2) Network, a functional genomics initiative, bridges the gap between cancer genomics and biology. The Network aims to understand how tumor heterogeneity leads to drug resistance in order to develop optimal combinations of chemotherapy or small molecules in combination with immunotherapy. 

Banner for CTD squared program. Links to CTD squared program page
Last updated: January 03, 2019

News & Publications

previousnext
Overview of the pathway and network analysis approach.
CTD²
February 05, 2020

The catalog of cancer driver mutations in protein-coding genes has greatly expanded in the past decade. However, non-coding cancer driver mutations are less well-characterized and only a handful of recurrent non-coding mutations, most notably TERT promoter mutations, have been reported. Here, as...

PIK3CA Protein
CTD²
February 01, 2020

Glioblastoma is a universally lethal form of brain cancer that exhibits an array of pathophysiological phenotypes, many of which are mediated by interactions with the neuronal microenvironment. Recent studies have shown that increases in neuronal activity have an important role in the...

Tumor-Associated Macrophages with Fluorescent Nanoparticles
CTD²
January 23, 2020

Macrophages (MΦ) play a critical role in tumor growth, immunosuppression and inhibition of adaptive immune responses in cancer. Hence, targeting signaling pathways in MΦs that promote tumor immunosuppression will provide therapeutic benefit. PI3Kγ has been recently established by our group and...

Surgery, Breast-Conserving, Female
CTD²
January 15, 2020

Dissemination is an essential early step in metastasis but its molecular basis remains incompletely understood. To define the essential targetable effectors of this process, we developed a 3D mammary epithelial culture model, in which dissemination is induced by overexpression of the...

CRISPR-Cas9 Editing of the Genome
CTD²
January 13, 2020

A lack of tools to precisely control gene expression has limited our ability to evaluate relationships between expression levels and phenotypes. Here, we describe an approach to titrate expression of human genes using CRISPR interference and series of single-guide RNAs (sgRNAs) with...

O
O
O
O
O